I would give $Novavax(NVAX)$a miss, as I prefer established pharmaceutical companie with a line of cash cows from approved drugs proven to treat common diseases and a long pipeline of drugs in various stages of clinical trials.

Examples of my preference are $Pfizer(PFE)$and $Merck(MRK)$that do not rely on a single drug for profitability, and whose earnings are stable. This is unlike Novavax which depends on the success of its COVID-19 vaccine and whose share price is highly volatile due to the high dependency on a single drug. This is not helped by the lateness of its COVID-19 vaccine, that falls far behind those of Pfizer, $BioNTech SE(BNTX)$and $Moderna, Inc.(MRNA)$that have been widely adopted by the western countries.

@TigerEvents@CaptainTiger@CaptainTiger@TigerWire@TigerStars